Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia | Aplastic Anemia & MDS International Foundation

Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia

Journal Title: 
Biol Blood Marrow Transplant
Primary Author: 
Georges GE
Author(s): 
Georges GE
Original Publication Date: 
Friday, January 11, 2019
Effective treatment for severe aplastic anemia (SAA) is either allogeneic bone marrow transplantation (BMT) [1,2] or nontransplant immunosuppressive therapy (IST) containing antithymocyte globulin (ATG) [3,4]. Both treatment approaches have advanced over the recent decades to achieve significantly improved outcomes. Considering that allogeneic BMT is a more durable treatment with a reduced risk of long-term complications and improved overall survival compared with IST, there is widespread consensus that BMT is the preferred first-line therapy for younger patients with SAA who have an HLA-matched sibling donor [1].
Bone Marrow Diseases: